A novel CAR‐T cell product targeting CD276 (also called B7‐H3), a member of the B7/CD28 family, has been determined the feasibility of antitumor activity against glioma ex vivo and in vivo studies4, 5 as well as several cases of preliminary clinical trial.6 This evidence concerns the gene CD276 and central nervous system cancer.